Menu
Currency
GWAS Study

Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.

Ziliak D, O'Donnell PH, Im HK et al.

21497773 PubMed ID
GWAS Study Type
239 Participants
31 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

ZD
Ziliak D
OP
O'Donnell PH
IH
Im HK
GE
Gamazon ER
CP
Chen P
DS
Delaney S
SS
Shukla S
DS
Das S
CN
Cox NJ
VE
Vokes EE
CE
Cohen EE
DM
Dolan ME
HR
Huang RS
Chapter II

Abstract

Summary of the research findings

Identifying patients prior to treatment who are more likely to benefit from chemotherapeutic agents or more likely to experience adverse events is an aim of personalized medicine. Pharmacogenomics offers a potential means of achieving this goal through the discovery of predictive germline genetic biomarkers. When applied particularly to the treatment of head and neck cancers, such information could offer significant benefit to patients as a means of potentially reducing morbidity associated with platinum-based chemotherapy. We developed a genome-wide, cell-based approach to identify single nucleotide polymorphisms (SNPs) associated with platinum susceptibility and then evaluated these SNPs as predictors for response and toxicity in head and neck cancer patients treated with platinum-based therapy as part of a phase II clinical trial. Sixty head and neck cancer patients were evaluated. Of 45 genome-wide SNPs examined, we found that 2 SNPs, rs6870861 (P=0.004; false discovery rate [FDR] <0.05) and rs2551038 (P=0.005; FDR <0.05), were associated significantly with overall response to carboplatin-based induction chemotherapy when incorporated into a model along with total carboplatin exposure. Interestingly, these 2 SNPs are associated strongly with the baseline expression of >20 genes (all P ≤10(-4)), and that 2 genes (SLC22A5 and SLCO4C1) are important organic cation/anion transporters known to affect platinum uptake and clearance. Several other SNPs were associated nominally with carboplatin-related hematologic toxicities. These findings demonstrate importantly that a genome-wide, cell-based model can identify novel germline genetic biomarkers of platinum susceptibility, which are replicable in a clinical setting with treated cancer patients and seem clinically meaningful for potentially enabling future personalization of care in such patients.

90 East Asian ancestry lymphoblastoid cell lines

Chapter III

Study Statistics

Key metrics and study information

239
Total Participants
GWAS
Study Type
Yes
Replicated
90 European ancestry lymphoblastoid cell lines, 59 Yoruban ancestry lymphoblastoid cell lines
Replication Participants
European, Sub-Saharan African, East Asian
Ancestry
U.S., Nigeria, Niger, China, Japan
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.